Latest Upsher-Smith Laboratories Inc. Stories
Studies Demonstrate Favorable Long-Term Safety Profile for Qudexy(TM) XR and Explore its Usefulness for Patients with Swallowing Difficulties WASHINGTON, April 21, 2015 /PRNewswire/ --
New Program Offers Support, Education, and Interactive Tools to Help Those Affected by Seizure Disorders MAPLE GROVE, Minn., April 10, 2015 /PRNewswire/ -- I Hate Seizures is the message
Company Recognizes 2014 Winners of the National Alliance of State Pharmacy Associations' Excellence in Innovation Award MAPLE GROVE, Minn., Feb.
FDA's Orange Book Updated to Reflect New Vogelxo(TM) Rating MAPLE GROVE, Minn., Feb.
Free Trial Offer, Co-Pay Program and Prior Authorization Assistance Now Available MAPLE GROVE, Minn., Feb.
Multiple Presentations Highlight Long-Term Safety, Tolerability, and Efficacy Measures, as Adjunctive Therapy for Patients with Refractory Partial-Onset Seizures SEATTLE, Dec.
Findings from Late-Breaking Abstract Demonstrate That Well-Defined Seizure Cluster Terminology is Necessary to Standardize Patient Diagnosis and Allow for Appropriate Treatment Strategies SEATTLE,
New Website Expands the Seizure Clusters Connect(TM) Community by Offering Information, Education and Resources to Support Patients and Caregivers MAPLE GROVE, Minn., Nov.
Findings Presented at 43rd Annual Meeting of the Child Neurology Society MAPLE GROVE, Minn., Oct.
Upsher-Smith Provides Funding to the Epilepsy Foundation to Commission Survey About Seizure Clusters, to be Conducted by Harris Poll® MAPLE GROVE, Minn., Sept.